Applying a dual-Scheimpflug camera to measure tear film thickness.


Journal

European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772

Informations de publication

Date de publication:
Jan 2022
Historique:
pubmed: 16 3 2021
medline: 21 1 2022
entrez: 15 3 2021
Statut: ppublish

Résumé

To assess the tear film thickness in healthy individuals by using a dual-Scheimpflug camera and topical 0.1% fluorescein. A prospective study on healthy individuals who underwent a bilateral tomography examination using the GALILEI dual-Scheimpflug with assessments of the thinnest and central corneal thickness (TCT and CCT, respectively), at baseline and 1 min after applying 2 and 4 µl of 0.1% fluorescein (30 min apart) under topical anesthesia with Oxybuprocaine 0.4%. Inclusion criteria were lack of dry eye disease symptoms and exclusion criteria were contact lens usage, eye drops usage, previous refractive surgery or any ocular surgery. All individuals scored zero on the ocular surface disease index (OSDI) questionnaire. A total of 62 eyes of 31 participants were included in this study. The mean age was 35.3 ± 10.88 (range 18-62). The mean TCT in was 549.16 µm in the right eye (RE) and 547.84 µm in the left eye (LE). After instillation of 2 µl of 0.1% fluorescein mean TCT increase by 27.84 µm in the RE and by 26.35 µm in the LE. CCT change was 27.58 µm increase in RE and 27.23 µm increase in LE. After instillation of 4 µl of 0.1% fluorescein the mean increase in TCT and CCT were 30.09 and 30.26 µm for OD and 28.33 and 30.15 µm for OS respectively. Comparison between the post instillation of 2 and 4 µl measurements showed no significant differences. Combining a dual-Scheimpflug camera and 0.1% fluorescein may serve as a method to assess the pre-corneal tear film.

Identifiants

pubmed: 33715472
doi: 10.1177/11206721211000274
doi:

Substances chimiques

Fluorescein TPY09G7XIR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

160-164

Auteurs

Shay Keren (S)

Ophthalmology Department, Tel-Aviv Medical Center, Affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK.

Michael Mimouni (M)

Department of Ophthalmology, Rambam Health Care Campus and the Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Ewan McCallum (E)

Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK.

Gilad Rabina (G)

Ophthalmology Department, Tel-Aviv Medical Center, Affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Eliya Levinger (E)

Ophthalmology Department, Tel-Aviv Medical Center, Affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH